[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545431":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":38,"responsibleParty":55,"collaborators":57,"id":72,"slug":25,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":25,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":25,"maxAge":25,"enrollmentInfo":79,"targetDuration":25,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":25,"overallStatus":40,"whyStopped":25,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"The First Affiliated Hospital of Soochow University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Haplo-cord HCT","EXPERIMENTAL","Patients enrolled in this arm will receive a coinfusion of cord blood unit in addition to a typical haploidentical hematopoietic cell transplantation",[13],"Biological: Haplo-cord HCT",{"label":15,"type":16,"description":17,"interventionNames":18},"Haplo-HCT","ACTIVE_COMPARATOR","Patients enrolled in this arm will receive a typical haploidentical hematopoietic cell transplantation",[19],"Biological: Haplo-HCT",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","Haploidentical hematopoietic cell transplantation will be performed with coinfusion of an unrelated cord blood unit",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Hematopoietic cell transplantation will be performed with a haploidentical donor",[15],[30],{"name":31,"affiliation":5,"role":32},"Yang XU","PRINCIPAL_INVESTIGATOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":25,"email":37},"CONTACT","86+051267781850","xuyang1020@126.com",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Suzhou","Jiangsu","215000","China",{"type":46,"coordinates":47},"Point",[48,49],120.59538,31.30408,{"lat":49,"lon":48},[52,53],{"name":31,"role":35,"phone":36,"phoneExt":25,"email":37},{"name":54,"role":32,"phone":25,"phoneExt":25,"email":25},"Yang Xu",{"type":56,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[58,60,62,64,66,68,70],{"name":59,"class":6},"Children's Hospital of Soochow University",{"name":61,"class":6},"Ruijin Hospital",{"name":63,"class":6},"Nanfang Hospital, Southern Medical University",{"name":65,"class":6},"Fujian Medical University Union Hospital",{"name":67,"class":6},"First Affiliated Hospital Xi'an Jiaotong University",{"name":69,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"name":71,"class":6},"Zhejiang University","100545431",false,"NCT06381817","Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients","Haploidentical Hematopoietic Cell Transplantation Combined With an Unrelated Cord Blood Unit for Acute T Cell Lymphoblastic Leukemia Compared to Haploidentical Hematopoietic Cell Transplantation: a Multicenter, Randomized, Open-label Trial","Inclusion Criteria:\n\n* Patients with acute T cell lymphoblastic leukemia\n* With available minimal residual disease parameters assessed by flow cytometry and\u002For quantitative polymerase chain reaction\n* Willing to undergo haploidentical hematopoietic cell transplantation and having a suitable haploidentical donor\n* With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3\n* Signing an informed consent form, having the ability to comply with study and follow-up procedures\n\nExclusion Criteria:\n\n* With other malignancies\n* Failing to acquire a suitable unrelated cord blood unit\n* With a previous history of autologous hematopoietic cell transplantation, allogeneic hematopoietic cell transplantation or chimeric antigen receptor T cell therapy\n* With uncontrolled infection intolerant to haploidentical hematopoietic cell transplantation\n* With severe organ dysfunction\n* In pregnancy or lactation period\n* With any conditions not suitable for the trial (investigators' decision)","ALL",{"count":80,"type":81},146,"ESTIMATED","INTERVENTIONAL",[84],"PHASE3","The goal of this clinical trial is to learn if haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit (haplo-cord HCT) works to treat acute T cell lymphoblastic leukemia (T-ALL). It will also learn about the safety of the transplantation. The main questions it aims to answer are:\n\nDose co-infusion of cord blood in haploidentical hematopoietic cell transplantation (haplo-HCT) lower the rate of relapse? What medical problems do participants have when having haplo-cord HCT? Researchers will compare haplo-cord HCT to haplo-HCT to see if haplo-cord HCT works to treat T-ALL.\n\nParticipants will be infused an unrelated cord blood unit at the same day of haploidentical graft infusion.",[87,88,89],"Acute T Cell Lymphoblastic Leukemia","Haploidentical Hematopoietic Stem Cell Transplantation","Cord Blood","2024-04-24",{"date":92,"type":93},"2024-04-26","ACTUAL",{"date":95,"type":93},"2024-04-01",{"date":97,"type":81},"2028-03-31",{"name":5,"class":6},1]